Italy Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the company has not only made significant R&D investments, but pursued key M&A and partnership deals, and aimed for global expansion.…
China Deng Haoqing, President and General Manager of Chiesi China, explores the company’s strategic growth in one of the world’s most dynamic healthcare markets. Deng discusses the alignment of Chiesi’s “AIR, CARE, and RARE” focus with China’s evolving healthcare priorities, highlighting efforts to bring innovation through local and global collaborations, including…
Hong Kong With its dual business approach – commercializing acquired products while developing a novel respiratory disease pipeline – Nuance Pharma, after closing Series D funding and establishing a solid revenue stream, has set its sights on Asia Pacific. Founder and CEO Mark Lotter, discusses the regulatory and talent acquisition challenges in…
Belgium Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of the Belgian firm’s recent history including expansion into the US, how a USD ten million injection of Series A financing…
Mexico Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico. With respiratory diseases, there is sometimes the erroneous perception that they are not as severe or urgent as other…
Sweden Niclas Källbom Karlsson, general manager of GSK Sweden, reflects on his first five years of heading the local affiliate, in which the company has emerged as a leader in the speciality respiratory medicines, vaccines and HIV area. With a new wave of products to be launched, he highlights the importance…
Thailand Thanakorn and Lakana Ounpiyodom of AeroCare highlight their unique positioning in the inhaler niche and how they have grown both their portfolio and facilities through strategic M&A. They share their strong interest in delivering the most innovative products in the field to Thai patients, and their wish to expand across…
China Kai Zhang, founder and chairman, and Sonia Wang, CEO, of Chinese respiratory technology specialist Omni Pharmaceuticals, discuss the respiratory market in China, how Omni plans to introduce four respiratory drugs onto the market within two years, and its focus on innovative new technologies. Unlike oncology, the inhalation market in…
Malaysia Saravanan G., group managing director of Biocare Group, details the opportunities he identified to create the first MDI (Metered Dose Inhalers) manufacturing plant in Malaysia. He also explains further the support received by the government for his initiatives and how the company will continue its efforts to bring more innovative…
Turkey Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest therapies in the respiratory and rare diseases areas. Meriç underlines the importance of motivating and developing a productive, dynamic and…
Poland Ewa Sek, general manager at ResMed Poland, explains the crucial role of ResMed in raising awareness on sleep apnea, COPD and other respiratory-related conditions in Poland and highlights the important investments that should be made to increase the diagnostics capabilities as well as to reimburse telemedicine and device accessories. ResMed…
Portugal Salvador Lopez saw an opportunity in the summer of 2015 to create the first Portuguese affiliate for Mundipharma. Three years on, he reveals how their business model, company culture and leadership has succeeded in disrupting the respiratory market with their blockbuster drug Flutiform, built the fastest growing subsidiary in Portugal…
See our Cookie Privacy Policy Here